VolitionRx begins first ovarian cancer detection study

open access

Q  Today we are focusing our interview on a new pilot study that VolitionRx is conducting in partnership with the Singapore General Hospital. Can you tell us a little about the study & its main aims/goals? How did the partnership with Singapore General Hospital come about?

Ovarian cancer is a huge problem in women's health. Known as a ‘silent killer’ because the early stages of the disease rarely exhibit symptoms and growths in the ovary are not palpable as other, for example breast, cancers may be. About 75% of ovarian cancers are not detected until after the disease has spread to the abdomen and more than 50% of patients die within 5 years of diagnosis. The study with Singapore General Hospital will be a pilot study – Singapore General Hospital will provide samples from 40 subjects and we will analyze them to assess the ability of our NuQ tests to detect ovarian cancer. We hope that, given positive results from the pilot study, we will be able to expand into further confirmatory trials in larger numbers of patients.......